Pharmaceutical Market Research Company in USA

For pharmaceutical and life-sciences decisions in the US market, BioNixus is a leading specialist: FDA-aligned study design, PBM and CMS payer context, HCP and KOL recruitment across major US academic medical centres, and outputs built for launch, market access, and lifecycle management teams.

Pharmaceutical market research in the USA is evidence generation for drug launch, market access, and lifecycle decisions across FDA, CMS, and PBM contexts. BioNixus focuses on physician behavior, payer and formulary dynamics, and institution-level adoption so commercial and access teams can prioritize US market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for the highest-spend products — 10 drugs from January 2026, expanding annually. This has significantly changed commercial strategy for products with Medicare exposure, particularly in cardiovascular, diabetes, and oncology. BioNixus conducts IRA impact research: payer and PBM formulary strategy studies, Medicare Part D beneficiary research, and commercial team intelligence on how MFPs (Maximum Fair Prices) affect market access dynamics.

BioNixus covers all major US payer segments: commercial insurance (employer-sponsored, ACA marketplace), Medicare Part B (physician-administered) and Part D (pharmacy-dispensed), Medicaid managed care, and PBM formulary committees (UnitedHealth/Optum, CVS/Caremark, Express Scripts/Cigna). Research includes in-depth interviews with medical directors and pharmacy benefit managers, formulary listing studies, PBM negotiation intelligence, and willingness-to-pay research.

Yes. BioNixus designs and executes US HCP research in compliance with IRB/OHRP requirements under 45 CFR Part 46 (Common Rule) and HIPAA/HITECH data privacy standards. For studies requiring IRB review, BioNixus supports protocol development and ethics documentation. All US respondent recruitment is consent-based with documented data handling procedures.

Scope drives cost: a focused US physician quantitative survey often starts in the low-to-mid five figures USD; full mixed-method access programs with PBM payer mapping and KOL depth interviews are higher. BioNixus scopes programs to one decision per phase so sponsors avoid unfocused fieldwork spend. The US premium physician market requires verified HCP recruitment and IRB-compliant protocols, which reflects in project pricing.

BioNixus recruits from major US academic medical centres (Mayo Clinic, Cleveland Clinic, Johns Hopkins, UCSF Medical Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital), large hospital systems (HCA Healthcare, Ascension, CommonSpirit), and community practice networks across all US regions. For specialty areas such as oncology or rare disease, we extend recruitment to NCI-designated cancer centres and rare disease specialty networks.

Yes. US modules can run standalone or with comparable cells in the UK, Germany, France, Brazil, Saudi Arabia, or UAE using consistent instruments — enabling global portfolio committees to benchmark US market dynamics against international markets with one research partner.